We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MVC-COV1901

News List

Medigen's MVC-COV1901 Selected for WHO COVID-19 Solidarity Trial Vaccines prnasia
October 27, 2021
Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation (WHO) Solidarity Trial Vaccines (STv).
Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine prnasia
October 18, 2021
The Lancet Respiratory Medicine, one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial...
Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant prnewswire
August 24, 2021
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation today announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.
First Participant Dosed in COVID-19 Vaccine Trial in Taiwan, China Region americanpharmaceuticalreview
January 29, 2021
Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901.